This section encompasses advances in all the major areas of liver disease. An important addition to this year's section is the contribution of Dr Sanyal on nonalcoholic fatty liver disease. The section on portal hypertension was an unexpected loss this year, but will return next year as will the section on cholestasis and cholestatic syndromes. Other topics will be introduced as clinical circumstances mandate. The contributors to this section have done a superb job of covering advances in their areas of expertise. I will focus on the highlights from each contribution.
Dr Lefkowitch (pp. 269-277) leads off with a review of hepatobiliary pathology. Important contributions were seen in a number of topics. International travel increases the likelihood of exposure to diseases not endemic to the US. There was a detailed description of the histology of hepatitis E; while there were findings similar to hepatitis A, portal lymphoid aggregates, a finding that makes us think of chronic conditions, was an unexpected finding in two cases [1] . There has been significant progress toward our understanding of the entity of IgG4-associated cholangitis, a part of the spectrum of autoimmune pancreatitis [2] . It is critical that the clinician recognize this condition given its responsiveness to immunosuppression. There have been advances in the characterization of benign liver lesions, particularly the entity of telangiectatic adenoma [3] . Two studies looked at specific immunohistochemical stains as a means to differentiate between hepatocellular carcinoma and metastatic cancer as well as between dysplastic nodules and well-differentiated hepatocellular carcinoma [4, 5] .
Drs Walzer and Kulik's update (pp. 312-319) on hepatocellular carcinoma (HCC) covered new data regarding the role of interferon-a to reduce recurrence of HCC after surgical resection. While overall there was no benefit, the subset of patients with stage III and IVA disease seemingly derived benefit [6] . Efforts to expand the Milan criteria continue; a study suggested tumor grade as determined by core biopsy may be an effective means of selecting patients with HCC for liver transplantation who exceed Milan criteria [7] . Two other studies also suggested that expan-sion beyond Milan criteria could be done without impacting survival rate [8, 9] . Despite the widely held belief that transplantation is superior to surgical resection for HCC, a study this year suggested otherwise [10] . A second study showed that there was improved survival with transplantation compared with resection for early HCC, but only if the waiting time to transplant was less than 4 months, something which is not possible in many parts of the US [11] . The importance of minimizing time on the transplant waiting list for patients with HCC was seemingly challenged by two studies that showed there was a significantly higher recurrence rate for living donor liver transplant (LDLT) than for deceased donor liver transplant [12, 13] . It was suggested this difference may be explained by LDLT allowing for the 'fast-tracking' of patients with aggressive tumor histology for transplant.
Drs Said and Lucey (pp. 339-345) reviewed the new literature on liver transplantation. The role of ablative therapies while awaiting liver transplantation is an area of active research. One study suggested that the lack of tumor progression after transarterial chemoembolization (TACE) correlates well with posttransplant survival, even in those patients that exceeded Milan criteria before TACE [14] . Recurrence of hepatitis C virus (HCV) after transplantation remains a significant problem. One study reported a remarkable sustained virological response (SVR) rate of 48% and suggested that early treatment (histology of F2 or less) was the key to optimizing response rates [15] . A systematic review of posttransplant HCV treatment showed a pooled SVR rate of 27% for pegylated interferon and ribavirin [16] . Many transplant centers will not retransplant patients with recurrent HCV. A new study suggested that careful patient selection can produce outcomes for patients with recurrent HCV that are comparable to other indications for transplantation [17] . A study has shown in an HCV replicon model possible antiviral effects of cyclosporine that would suggest it might be a better choice than tacrolimus for patients transplanted for HCV [18] . Use of extended criteria donors has greatly increased the donor pool. Many groups preferentially use these organs in patients with low model for end-stage liver disease (MELD) scores; however, a group of researchers found that the patients with high MELD scores may also benefit from these organs [19] . finding that will change clinical practice [20] . Entecavir continued to show a favorable resistance profile in nucleoside naïve patients; 13 out of 243 hepatitis B 'e' antigen (HBeAg)-positive patients treated for 96 weeks with entecavir developed virologic breakthrough, but none had genotypic resistance [21] . The resistance data in lamivudine-resistant patients was not so positive; 9% of lamivudine-resistant patients treated with high-dose entecavir for 96 weeks developed entecavir resistant mutations [22] . Entecavir was also found to select for the M184V mutation in HIV, prompting warnings regarding the use of entecavir in HIV patients not on highly active antiretroviral therapy [23] . The cumulative probability of development of adefovir resistance mutations in adefovir monotherapy in nucleoside-naïve HBeAg-negative patients was 29% after 5 years of therapy, a finding that should raise concerns regarding using adefovir as a monotherapy in HBeAgnegative patients [24] . Data on the next-generation therapies for HCV continue to gather; telaprevir and boceprevir, both protease inhibitors, had encouraging results of phase I/II studies published. [25, 26] . A study showed that shortening the duration of therapy from 24 to 16 weeks in genotype 2/3 patients produced lower SVR rates, even in those patients that achieved a rapid virologic response [27] .
Dr Czaja (pp. 298-305) reviewed the new literature on autoimmune hepatitis (AIH). There is a growing understanding of the pathogenesis of AIH; two reports showed that different geographical regions and ethnic groups have different susceptibility alleles [28, 29] . A study showed the importance of avoiding disease relapses; the goal of therapy needs to be a complete and sustained disease remission [30] . Unfortunately, defining an endpoint of therapy that correlates with full resolution of disease remains a challenge [31] . There was yet another study verifying that centrilobular necrosis falls within the histologic spectrum of AIH [32] . A study showed that CD8 þ T lymphocytes that are HLA-A2-restricted and specific for CYP2D6 characterize type 2 AIH, and generate immune responses that correlate with the stage of disease and degree of inflammation [33] . Others showed that African-Americans, particularly males, have more advanced disease on presentation and poorer outcomes than other ethnic groups [34] . Dr Lewis (pp. 287-297) covers the topic of drug-induced liver injury (DILI). One study showed how the nature of DILI in Asia is very different than in the west; over 50% of the reported cases from Asia were caused by traditional herbs, many products containing adulterants [35] . A US Food and Drug Administration-sponsored proposal of biochemical parameters for predicting DILI in clinical trials was published [36] . An important trial published in the past year was the first randomized controlled trial of a statin drug in patients with chronic liver disease, mostly nonalcoholic fatty liver disease and chronic hepatitis C [37] . This study verified the safety of pravastatin in this group of patients and will hopefully help reduce the general anxiety of using this class of drugs in patients with chronic liver disease. Dr Sanyal (pp. 320-327) writes the inaugural review of nonalcoholic fatty liver disease (NAFLD) for Current Opinion in Gastroenterology; he provides both a review of the important past literature as well as the important advances of the past year. A study verified that hepatic triglyceride accumulation is the hallmark of NAFLD and there is also an increase in diacylglycerol, a metabolically active molecule [38] . There has been growing data detailing the natural history of NAFLD. One study showed that 15% of subjects with nonalcoholic steatohepatitis (NASH) progressed to cirrhosis over a 10-to 15- year timeframe, while a second study showed that subjects with cirrhosis secondary to NASH decompensate at a rate of 4% per year [39, 40] . Treatment of NAFLD remains limited. Oral insulin-sensitizing agents have been an area of active research and a placebo-controlled trial suggested benefit of pioglitazone, although the enthusiasm needs to be tempered by the limitations of the trial [41] .
Dr Reuben (pp. 328-338) provides the update on alcohol and the liver. As a means for primary care physicians to screen for excessive alcohol consumption, a single question ['When was the last time you had more than four drinks (for men) or five drinks (for women) in one day?'] had comparable sensitivity to the more involved Alcohol Use Disorders Identification Test [42] . There is continued debate about the utility of carbohydrate-deficient transferrin as an indirect marker of heavy alcohol use [43, 44] . Ethyl glucuronide has potential as a direct marker of excessive alcohol use [45] [46] [47] . Alcohol was shown to have a deleterious effect on the outcomes of HCV treatment, but seemingly by reducing the likelihood of full compliance with the treatment regimen [48] .
Drs Taddei, Mistry and Schilsky (pp. 278-287) review this year's literature related to inherited metabolic diseases. Our understanding of iron-overload conditions continues to advance. The central role of the peptide hepcidin has been better elucidated and one expert likened hemochromatosis to diabetes, with the liver being the primary endocrine organ and hepcidin the effector hormone [49] . Alcohol was found to inhibit hepcidin even in the presence of iron overload, providing insight into the iron overload often seen in these patients [50] . A study suggested that the general impression that patients transplanted for hemochromatosis do less well than patients with other diagnoses may need to be reconsidered [51] . We were reminded that Wilson disease should remain in the differential of causes of chronic liver disease in patients over the age of 40. Three patients over the age of 40 were diagnosed with Wilson disease via conventional means and verified with molecular diagnostics [52] .
